Connect your AI

Stoke Therapeutics, Inc. STOK Earnings yield

Earnings yield at other companies

Ionis PharmaceuticalsIONS

-2.6%-1.1pp

Jazz PharmaceuticalsJAZZ

-4.6%-11.2pp

Xenon PharmaceuticalsXENE

-6.9%-1.6pp

Praxis Precision Medicines, Inc.PRAX

-3.6%-1.7pp

Harmony Biosciences Holdings, Inc.HRMY

9%+1.0pp

Nurix Therapeutics, Inc.NRIX

-18%+0.2pp

Other financials

Income statement

Revenue$6.2M-96.1%

Operating income-$53.4M-148%

Net income-$50.0M-144%

EPS (diluted)-$0.79-142%

Balance sheet

Cash & equivalents$155.7M-43.4%

Total debt$3.4M-42.5%

Total equity$394.9M+12.8%

Total assets$443.3M+8.9%

Cash flow

Operating cash flow-$60.6M-146%

CapEx$353.0K+132%

Free cash flow-$60.9M-146%

Valuation

Market cap$1.94B+436%

Enterprise value$1.79B+1,855%

P/S60.4×+58.5×

Profitability

Operating margin-577.5%-597pp

Net margin-529.2%-556pp

FCF margin36.2%+18.4pp

Returns & leverage

Return on equity-45.6%-66.1pp

Debt / equity0×0.0×

Current ratio9×+0.6×

Where this comes from

Calculated from Stoke Therapeutics, Inc.’s reported figures.

net income/market cap=-8.8%

Based on trailing twelve months.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Stoke Therapeutics, Inc.'s earnings yield?: Stoke Therapeutics, Inc. (STOK) reported earnings yield of -8.8% in Q1 2026.
How has Stoke Therapeutics, Inc.'s earnings yield changed year-over-year?: Stoke Therapeutics, Inc.'s earnings yield decreased by 163.1% year-over-year, from 14% to -8.8%.
What is the long-term trend for Stoke Therapeutics, Inc.'s earnings yield?: Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s earnings yield has grown at a -30.2% compound annual growth rate (CAGR), from -2.3% to -0.4%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.